Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs

被引：64

作者：

Burris, H. A., III ^{[1
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN 37203 USA

来源：

ONCOGENE | 2009年 / 28卷

关键词：

NSCLC; non-small-cell lung cancer; EGFR; resistance; dual EGFR/VEGF inhibition; antiangiogenesis; GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITORS; RANDOMIZED PHASE-III; CHEMOTHERAPY-NAIVE PATIENTS; CISPLATIN PLUS GEMCITABINE; ACQUIRED-RESISTANCE; KRAS MUTATIONS; EGFR MUTATION; TRIAL; CARBOPLATIN;

D O I：

10.1038/onc.2009.196

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Non-small-cell lung cancer (NSCLC) is a major global health problem and is the leading cause of cancer death worldwide. Current treatment involves nonspecific, nonselective cytotoxic chemotherapy, which results in only a modest increase in survival and causes significant toxicity to the patient. Targeted agents are initially effective in certain small subpopulations of patients, but eventually nearly all patients become resistant to further treatment. The limitations in efficacy and safety associated with available treatments for NSCLC underscore the need for novel agents with improved efficacy and safety profiles. This review discusses the limitations of currently recommended therapies for patients with advanced NSCLC and discusses new agents in clinical development for this disease. Oncogene (2009) 28, S4-S13; doi:10.1038/onc.2009.196

引用

页码：S4 / S13

页数：10

共 78 条

[1]

Abrams TJ, 2003, MOL CANCER THER, V2, P1011

[2] The Bcl-2 apoptotic switch in cancer development and therapy [J].

Adams, J. M. ;

Cory, S. .

ONCOGENE, 2007, 26 (09) :1324-1337

[3]

[Anonymous], 2008, CLIN PRACT GUID NONS

[4] Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors [J].

Balak, Marissa N. ;

Gong, Yixuan ;

Riely, Gregory J. ;

Somwar, Romel ;

Li, Allan R. ;

Zakowski, Maureen F. ;

Chiang, Anne ;

Yang, Guangli ;

Ouerfelli, Ouathek ;

Kris, Mark G. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2006, 12 (21) :6494-6501

[5] The epidermal growth factor receptor family [J].

Bazley, LA ;

Gullick, WJ .

[6] Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide [J].

Bolonaki, Irini ;

Kotsakis, Athanassios ;

Papadimitraki, Elsa ;

Aggouraki, Despoina ;

Konsolakis, George ;

Vagia, Aphrodite ;

Christophylakis, Charalambos ;

Nikoloudi, Irini ;

Magganas, Elefterios ;

Galanis, Athanassios ;

Cordopatis, Paul ;

Kosmatopoulos, Kostas ;

Georgoulias, Vassilis ;

Mavroudis, Dimitris .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (19) :2727-2734

[7] Alteration of pemetrexed excretion in the presence of acute renal failure and effusions: Presentation of a case and review of the literature [J].

Brandes, JC ;

Grossman, SA ;

Ahmad, H .

CANCER INVESTIGATION, 2006, 24 (03) :283-287

[8] Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: Sobering results [J].

Breathnach, OS ;

Freidlin, B ;

Conley, B ;

Green, MR ;

Johnson, DH ;

Gandara, DR ;

O'Connell, M ;

Shepherd, FA ;

Johnson, BE .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1734-1742

[9]

Britten CD, 2004, MOL CANCER THER, V3, P1335

[10]

CAMPOS L, 1993, BLOOD, V81, P3091

← 1 2 3 4 5 6 7 8 →